

Supplementary Materials, Annex Table 5A. Progression-free survival based on the number of previous lines in pNENs.

N. of previous lines	N/n	Median PFS (months)	95% CI
0-1	59/16	66.2	25.0-NR
2	55/32	17.0	14.7-27.2
>2	68/42	14.6	11.9-28.6

Supplementary Materials, Annex Table 5B. Progression-free survival based on the number of previous lines in midgut NENs.

N. of previous lines	N/n	Median PFS (months)	95% CI
0-1	74/19	50.8	27.1-NR
2	48/19	29.3	22.7-NR
>2	26/15	23.3	15.2-NR

Supplementary Materials, Annex Table 5C. Progression-free survival based on the number of previous lines in BP-NENs.

N. of previous lines	N/n	Median PFS (months)	95% CI
0-1	14/7	33.1	18.18-NR
2	21/11	16.8	8.38-NR
>2	21/16	17.3	9.86-NR

Supplementary Materials, Annex Table 5D. Progression-free survival based on the number of previous lines in PPGLs.

N. of previous lines	N/n	Median PFS (months)	95% CI
0-1	18/5	45.27	30.58-NR
2	5/3	12.43	9.73-NR
>2	8/7	9.34	7.53-NR

Supplementary Materials, Annex Table 5E. Progression-free survival based on the number of previous lines in other GEP-NENs.

N. of previous lines	N/n	Median PFS (months)	95% CI
0-1	22/6	NA	42.31-NR
2	16/7	20.0	12.85-NR
>2	22/16	16.6	9.93-NR

Supplementary Materials, Annex Table 5F. Progression-free survival based on the number of previous lines in other NGEp-NENs.

N. of previous lines	N/n	Median PFS (months)	95% CI
0-1	19/7	19.1	19.07-NR
2	10/4	36.6	10.75-NR
>2	16/13	16.2	9.86-NR

Abbreviations: N/n, sample/events; PFS, progression-free survival; CI, confidence interval; pNEN, pancreatic neuroendocrine neoplasm; BP-NEN, bronchopulmonary neuroendocrine neoplasm; PPGL, pheochromocytoma and paraganglioma; NEN, neuroendocrine neoplasm: GEP, gastroenteropancreatic; NGEF, no gastroenteropancreatic; PD, progression disease: SD, stable disease; PR, partial response; CR, complete response, N., number.